1,640 Shares in Labcorp Holdings Inc. $LH Bought by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP purchased a new stake in shares of Labcorp Holdings Inc. (NYSE:LH – Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 1,640 shares of the medical research company’s stock, valued at approximately $506,000.

A number of other hedge funds have also recently bought and sold shares of LH. Allied Private Wealth LLC bought a new stake in shares of Labcorp in the second quarter worth $33,000. William Mack & Associates Inc. acquired a new stake in Labcorp during the third quarter worth about $42,000. Pathway Financial Advisers LLC acquired a new stake in shares of Labcorp during the 3rd quarter worth approximately $43,000. Jones Financial Companies Lllp acquired a new stake in Labcorp in the second quarter worth $58,000. Finally, Ancora Advisors LLC bought a new stake in Labcorp in the 2nd quarter valued at about $67,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Trading Up 0.1%

Labcorp stock opened at $370.69 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.22 and a current ratio of 1.41. The business’s 50-day simple moving average is $329.60 and its 200-day simple moving average is $292.58. The firm has a market capitalization of $30.10 billion, a PE ratio of 30.41, a PEG ratio of 2.09 and a beta of 0.86. Labcorp Holdings Inc. has a 52 week low of $245.00 and a 52 week high of $375.10.

Labcorp (NYSE:LH – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The medical research company reported $4.78 EPS for the quarter, topping analysts’ consensus estimates of $4.64 by $0.14. Labcorp had a return on equity of 17.13% and a net margin of 6.88%. The company had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the company earned $4.18 earnings per share. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. Equities research analysts forecast that Labcorp Holdings Inc. will post 18.51 earnings per share for the current year.

Labcorp Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Tuesday, November 24th will be given a $0.72 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.8%. Labcorp’s dividend payout ratio (DPR) is currently 23.63%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on LH. Piper Sandler boosted their price target on Labcorp from $300.00 to $309.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. HSBC upgraded shares of Labcorp from a “hold” rating to a “buy” rating and set a $410.00 price target on the stock in a research report on Thursday, November 5th. Barclays boosted their price objective on Labcorp from $330.00 to $380.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 28th. JPMorgan Chase & Co. increased their target price on Labcorp from $330.00 to $360.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. Finally, Deutsche Bank restated a “hold” rating and set a $355.00 price target on shares of Labcorp in a report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Labcorp currently has a consensus rating of “Moderate Buy” and an average target price of $369.08.

Check Out Our Latest Stock Report on LH

Insider Buying and Selling

In other Labcorp news, EVP Bryan T. Vaughn sold 306 shares of Labcorp stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $353.70, for a total transaction of $108,232.20. Following the sale, the executive vice president directly owned 6,845 shares of the company’s stock, valued at approximately $2,421,076.50. The trade was a 4.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Brian J. Caveney sold 2,000 shares of the company’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $372.04, for a total value of $744,080.00. Following the completion of the sale, the executive vice president owned 34,562 shares in the company, valued at $12,858,446.48. This trade represents a 5.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,384 shares of company stock valued at $1,241,707 over the last ninety days. 0.84% of the stock is owned by company insiders.

About Labcorp

(Free Report)

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.

Featured Stories

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH – Free Report).

Institutional Ownership by Quarter for Labcorp (NYSE:LH)

Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.